MorphoSys AG (MOR): Price and Financial Metrics

MorphoSys AG (MOR): $13.98

0.20 (+1.45%)

POWR Rating

Component Grades














  • MOR scores best on the Value dimension, with a Value rank ahead of 77.49% of US stocks.
  • MOR's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • MOR's current lowest rank is in the Growth metric (where it is better than 9.18% of US stocks).

MOR Stock Summary

  • MorphoSys AG's stock had its IPO on April 19, 2018, making it an older stock than merely 9.51% of US equities in our set.
  • Over the past twelve months, MOR has reported earnings growth of -206.54%, putting it ahead of only 10.05% of US stocks in our set.
  • Revenue growth over the past 12 months for MorphoSys AG comes in at -57.82%, a number that bests merely 5.36% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to MorphoSys AG, a group of peers worth examining would be SRT, RIG, GSAT, HDSN, and SMHI.
  • Visit MOR's SEC page to see the company's official filings. To visit the company's web site, go to

MOR Valuation Summary

  • MOR's price/earnings ratio is -12; this is 135.29% lower than that of the median Healthcare stock.
  • Over the past 40 months, MOR's price/sales ratio has gone down 28.5.
  • Over the past 40 months, MOR's price/sales ratio has gone down 28.5.

Below are key valuation metrics over time for MOR.

Stock Date P/S P/B P/E EV/EBIT
MOR 2021-02-04 12.2 6.2 138.5 39.0
MOR 2020-12-10 11.7 5.9 132.2 37.5
MOR 2020-03-16 36.9 5.9 -27.3 -26.5
MOR 2019-08-13 34.3 8.4 -93.5 -89.4
MOR 2019-07-09 40.7 6.7 -55.3 -51.9
MOR 2018-11-13 53.5 6.7 -51.2 -51.6

MOR Stock Price Chart Interactive Chart >

Price chart for MOR

MOR Price/Volume Stats

Current price $13.98 52-week high $34.99
Prev. close $13.78 52-week low $13.21
Day low $13.87 Volume 78,726
Day high $14.28 Avg. volume 84,916
50-day MA $19.15 Dividend yield N/A
200-day MA $24.19 Market Cap 1.84B

MorphoSys AG (MOR) Company Bio

MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.

MOR Latest News Stream

Event/Time News Detail
Loading, please wait...

MOR Latest Social Stream

Loading social stream, please wait...

View Full MOR Social Stream

Latest MOR News From Around the Web

Below are the latest news stories about MorphoSys AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

MorphoSys reports Q2 results

MorphoSys (MOR): Q2 GAAP EPS of €0.61.Revenue of €38.2M (+100% Y/Y)Press Release...

Seeking Alpha | July 29, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Greetings, trader!

William White on InvestorPlace | July 27, 2021

MorphoSys Updates FY Revenues Outlook

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) said it now expects group revenues for fiscal year 2021 to be in the range of 155 million euros to 180 million euros compared to the prior outlook of 150

FinanzNachrichten | July 26, 2021

MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announces today an update of its financial guidance for 2021 after preliminary completion of the latest evaluation of MorphoSys' half year 2021 financial performance.

Yahoo | July 26, 2021

MorphoSys AG: Invitation to MorphoSys'' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologie

FinanzNachrichten | July 21, 2021

Read More 'MOR' Stories Here

MOR Price Returns

1-mo -30.59%
3-mo -41.63%
6-mo -53.37%
1-year -57.42%
3-year -57.84%
5-year N/A
YTD -50.67%
2020 -20.55%
2019 40.99%
2018 N/A
2017 N/A
2016 N/A

Continue Researching MOR

Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:

MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8034 seconds.